The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Stomach Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Stomach Neoplasms


Psychiatry related information on Stomach Neoplasms


High impact information on Stomach Neoplasms


Chemical compound and disease context of Stomach Neoplasms


Biological context of Stomach Neoplasms


Anatomical context of Stomach Neoplasms


Gene context of Stomach Neoplasms

  • CONCLUSIONS: The inhibitory effect on JNK-c-Jun/AP-1 activation contributes to the antitumor effect of COX-2-specific inhibitor, and inhibition of JNK activation may have a therapeutic benefit against gastric cancer [27].
  • Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin [28].
  • The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells [29].
  • CONCLUSIONS: These results indicate that genetic alterations of TFF1 may lead to gastric mucosal barrier defects and contribute to the pathogenesis of gastric cancer [30].
  • H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells [31].
  • The strong associations between MTHFD variants and the plasma tHcy levels and gastric cancer risk suggest, for the first time, a possible gene-environment interaction between genetic variants of folate-metabolizing genes and high tHcy levels in gastric carcinogenesis [32].
  • This meta-analysis suggests that the CYP2E1 PstI/RsaI polymorphism may be a risk factor for gastric cancer in Asians, and that a synergic relation among GSTM1 and CYP2E1 may account for a proportion of gastric cancer cases [33].
  • These results suggest that genetic alteration of the ATBF1 gene may contribute to the aggressive nature of gastric cancers and the production of AFP in gastric cancer cells [34].
  • H. pylori augmented the growth of gastric cancers via the LPS-TLR4 pathway, whereas it attenuated the antitumor activity and IFN-gamma-mediated cellular immunity of MNC [35].
  • In asymptomatic controls, only Reprimo was infrequently methylated in comparison with plasma from gastric cancer cases (P < 0.001) [36].
  • Ectopic expression of miR-146a inhibited migration and invasion and downregulated EGFR and IRAK1 expression in gastric cancer cells [37].

Analytical, diagnostic and therapeutic context of Stomach Neoplasms


  1. External imaging of gastric-cancer metastases with radiolabelled CEA and CSAp antibodies. Nelson, M.O., DeLand, F.H., Shocat, D., Bennett, S.J., Goldenberg, D.M. N. Engl. J. Med. (1983) [Pubmed]
  2. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S.L., Galle, P.R., Stremmel, W., Oren, M., Krammer, P.H. J. Exp. Med. (1998) [Pubmed]
  3. Gastrin protection against chemically induced gastric adenocarcinomas in Wistar rats: histopathology of the glandular stomach and incidence of gastric adenocarcinoma. Tatsuta, M., Yamamura, H., Taniguchi, H., Tamura, H. J. Natl. Cancer Inst. (1982) [Pubmed]
  4. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Huang, J.Q., Zheng, G.F., Sumanac, K., Irvine, E.J., Hunt, R.H. Gastroenterology (2003) [Pubmed]
  5. p53 gene mutations in gastric and esophageal cancers. Imazeki, F., Omata, M., Nose, H., Ohto, M., Isono, K. Gastroenterology (1992) [Pubmed]
  6. Methylenetetrahydrofolate reductase 677C>T polymorphism and gastric cancer susceptibility in Mexico. Lacasaña-Navarro, M., Galván-Portillo, M., Chen, J., López-Cervantes, M., López-Carrillo, L. Eur. J. Cancer (2006) [Pubmed]
  7. Gastric carcinogenesis: diet as a causative factor. Sugimura, T., Wakabayashi, K. Medical oncology and tumor pharmacotherapy. (1990) [Pubmed]
  8. Mortality at ages 75 and older in the Cancer Prevention Study (CPS I). Lew, E.A., Garfinkel, L. CA: a cancer journal for clinicians. (1990) [Pubmed]
  9. Causal relationship between the loss of RUNX3 expression and gastric cancer. Li, Q.L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, K., Chi, X.Z., Lee, K.Y., Nomura, S., Lee, C.W., Han, S.B., Kim, H.M., Kim, W.J., Yamamoto, H., Yamashita, N., Yano, T., Ikeda, T., Itohara, S., Inazawa, J., Abe, T., Hagiwara, A., Yamagishi, H., Ooe, A., Kaneda, A., Sugimura, T., Ushijima, T., Bae, S.C., Ito, Y. Cell (2002) [Pubmed]
  10. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. Huntsman, D.G., Carneiro, F., Lewis, F.R., MacLeod, P.M., Hayashi, A., Monaghan, K.G., Maung, R., Seruca, R., Jackson, C.E., Caldas, C. N. Engl. J. Med. (2001) [Pubmed]
  11. Mortality among workers exposed to ethylene oxide. Steenland, K., Stayner, L., Greife, A., Halperin, W., Hayes, R., Hornung, R., Nowlin, S. N. Engl. J. Med. (1991) [Pubmed]
  12. Nitrate and gastric cancer risks. Tannenbaum, S.R., Correa, P. Nature (1985) [Pubmed]
  13. Gastric cancer and salivary nitrate and nitrite. Mirvish, S.S. Nature (1985) [Pubmed]
  14. Induction of human autologous cytotoxic T lymphocytes on formalin-fixed and paraffin-embedded tumour sections. Liu, S.Q., Saijo, K., Todoroki, T., Ohno, T. Nat. Med. (1995) [Pubmed]
  15. High concentrations of glutathione in glandular stomach: possible implications for carcinogenesis. Body, S.C., Sasame, H.A., Body, M.R. Science (1979) [Pubmed]
  16. Gastric cancer: current status of treatment. Carter, S.K., Comis, R.L. J. Natl. Cancer Inst. (1977) [Pubmed]
  17. Ramucirumab: successfully targeting angiogenesis in gastric cancer. Javle, M., Smyth, E.C., Chau, I. Clin. Cancer Res. (2014) [Pubmed]
  18. Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Grady, W.M., Willis, J., Guilford, P.J., Dunbier, A.K., Toro, T.T., Lynch, H., Wiesner, G., Ferguson, K., Eng, C., Park, J.G., Kim, S.J., Markowitz, S. Nat. Genet. (2000) [Pubmed]
  19. Diet and chronic atrophic gastritis: a case-control study. Fontham, E., Zavala, D., Correa, P., Rodriguez, E., Hunter, F., Haenszel, W., Tannenbaum, S.R. J. Natl. Cancer Inst. (1986) [Pubmed]
  20. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. El-Omar, E.M., Rabkin, C.S., Gammon, M.D., Vaughan, T.L., Risch, H.A., Schoenberg, J.B., Stanford, J.L., Mayne, S.T., Goedert, J., Blot, W.J., Fraumeni, J.F., Chow, W.H. Gastroenterology (2003) [Pubmed]
  21. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Silberg, D.G., Sullivan, J., Kang, E., Swain, G.P., Moffett, J., Sund, N.J., Sackett, S.D., Kaestner, K.H. Gastroenterology (2002) [Pubmed]
  22. Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: Role of Rho GTPase and menin. Varro, A., Hemers, E., Archer, D., Pagliocca, A., Haigh, C., Ahmed, S., Dimaline, R., Dockray, G.J. Gastroenterology (2002) [Pubmed]
  23. Physicochemical properties and isoenzyme composition of hexokinase from normal and malignant human tissues. Monakhov, N.K., Neistadt, E.L., Shavlovskil, M.M., Shvartsman, A.L., Neĭfakh, S.A. J. Natl. Cancer Inst. (1978) [Pubmed]
  24. Protein synthesis in hepatocytes isolated from patients with gastrointestinal malignancy. Starnes, H.F., Warren, R.S., Brennan, M.F. J. Clin. Invest. (1987) [Pubmed]
  25. Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Ishige, I., Usui, Y., Takemura, T., Eishi, Y. Lancet (1999) [Pubmed]
  26. Gastric-juice nitrite and gastric cancer. Jones, S.M., Davies, P.W., Savage, A. Lancet (1978) [Pubmed]
  27. Cyclooxygenase-2 inhibitor (SC-236) suppresses activator protein-1 through c-Jun NH2-terminal kinase. Wong, B.C., Jiang, X.H., Lin, M.C., Tu, S.P., Cui, J.T., Jiang, S.H., Wong, W.M., Yuen, M.F., Lam, S.K., Kung, H.F. Gastroenterology (2004) [Pubmed]
  28. Regulation of growth of human gastric cancer by gastrin and glycine-extended progastrin. Iwase, K., Evers, B.M., Hellmich, M.R., Guo, Y.S., Higashide, S., Kim, H.J., Townsend, C.M. Gastroenterology (1997) [Pubmed]
  29. The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Tanida, S., Joh, T., Itoh, K., Kataoka, H., Sasaki, M., Ohara, H., Nakazawa, T., Nomura, T., Kinugasa, Y., Ohmoto, H., Ishiguro, H., Yoshino, K., Higashiyama, S., Itoh, M. Gastroenterology (2004) [Pubmed]
  30. Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Park, W.S., Oh, R.R., Park, J.Y., Lee, J.H., Shin, M.S., Kim, H.S., Lee, H.K., Kim, Y.S., Kim, S.Y., Lee, S.H., Yoo, N.J., Lee, J.Y. Gastroenterology (2000) [Pubmed]
  31. H. pylori activates NF-kappaB through a signaling pathway involving IkappaB kinases, NF-kappaB-inducing kinase, TRAF2, and TRAF6 in gastric cancer cells. Maeda, S., Yoshida, H., Ogura, K., Mitsuno, Y., Hirata, Y., Yamaji, Y., Akanuma, M., Shiratori, Y., Omata, M. Gastroenterology (2000) [Pubmed]
  32. Polymorphisms of MTHFD, plasma homocysteine levels, and risk of gastric cancer in a high-risk Chinese population. Wang, L., Ke, Q., Chen, W., Wang, J., Tan, Y., Zhou, Y., Hua, Z., Ding, W., Niu, J., Shen, J., Zhang, Z., Wang, X., Xu, Y., Shen, H. Clin. Cancer Res. (2007) [Pubmed]
  33. CYP2E1PstI/RsaI polymorphism and interaction with tobacco, alcohol and GSTs in gastric cancer susceptibility: A meta-analysis of the literature. Boccia, S., De Lauretis, A., Gianfagna, F., van Duijn, C.M., Ricciardi, G. Carcinogenesis (2007) [Pubmed]
  34. Genetic alterations of the ATBF1 gene in gastric cancer. Cho, Y.G., Song, J.H., Kim, C.J., Lee, Y.S., Kim, S.Y., Nam, S.W., Lee, J.Y., Park, W.S. Clin. Cancer Res. (2007) [Pubmed]
  35. Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Chochi, K., Ichikura, T., Kinoshita, M., Majima, T., Shinomiya, N., Tsujimoto, H., Kawabata, T., Sugasawa, H., Ono, S., Seki, S., Mochizuki, H. Clin. Cancer Res. (2008) [Pubmed]
  36. Reprimo as a potential biomarker for early detection in gastric cancer. Bernal, C., Aguayo, F., Villarroel, C., Vargas, M., Díaz, I., Ossandon, F.J., Santibáñez, E., Palma, M., Aravena, E., Barrientos, C., Corvalan, A.H. Clin. Cancer Res. (2008) [Pubmed]
  37. Clinical Significance of miR-146a in Gastric Cancer Cases. Kogo, R., Mimori, K., Tanaka, F., Komune, S., Mori, M. Clin. Cancer Res. (2011) [Pubmed]
  38. Loss of Klf4 in mice causes altered proliferation and differentiation and precancerous changes in the adult stomach. Katz, J.P., Perreault, N., Goldstein, B.G., Actman, L., McNally, S.R., Silberg, D.G., Furth, E.E., Kaestner, K.H. Gastroenterology (2005) [Pubmed]
  39. Histamine-2-receptor antagonists and gastric cancer risk. La Vecchia, C., Negri, E., D'Avanzo, B., Franceschi, S. Lancet (1990) [Pubmed]
  40. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. MacDonald, J.S., Schein, P.S., Woolley, P.V., Smythe, T., Ueno, W., Hoth, D., Smith, F., Boiron, M., Gisselbrecht, C., Brunet, R., Lagarde, C. Ann. Intern. Med. (1980) [Pubmed]
  41. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. Ott, K., Fink, U., Becker, K., Stahl, A., Dittler, H.J., Busch, R., Stein, H., Lordick, F., Link, T., Schwaiger, M., Siewert, J.R., Weber, W.A. J. Clin. Oncol. (2003) [Pubmed]
WikiGenes - Universities